Abstract 299P
Background
Nasopharyngeal cancer is the most common head and neck cancer in Indonesia with prevalence of 28.4% among all adult head and neck cancer. Radiotherapy and chemotherapy are the main modalities for nasopharyngeal cancer treatment, With proper treatment, patients with nasopharyngeal cancer would have 5-year survival rate of above 80%, even in locally advanced nasopharyngeal cancer. However toxicity associated with nasopharyngeal cancer treatment is quite burdensome for the patients especially toxicity in terms of hematology, mucositis, nausea, and vomiting. Due to the burdening toxicity of chemoradiation treatment for the patients, several chemotherapy schedules were attempted. We aimed to search and elucidate high quality evidence available to date to answer our clinical question, whether triweekly or weekly concurrent chemoradiation is better for nasopharyngeal cancer treatment in terms of survival.
Methods
Literature searching was conducted on 3 databases: PubMed, EBSCOhost, and Scopus using keyword “Nasopharyngeal Cancer”, “Weekly Chemotherapy”, “Triweekly Chemotherapy”, “Overall Survival” and its synonyms using both MeSH and non-MeSH terms. Critical Appraisal for selected studies was done by 3 different person, using CEBM Critical Appraisals Tools.
Results
Six studies were selected to be relevant after elaborate search, which was then critically apprasied and found to be valid. Results from all those 6 studies found that weekly vs. triweekly chemoradiation regimen leads to similar survival outcome in nasopharyngeal cancer patients. Overall Survival (OS) rates from those 6 studies showed comparable result among both regimens (3-Year OS, 91% vs 90.8%; 5-year OS, 89% vs. 91%, 85.6% vs 90%, 78.9% vs 85.2%) and, all OS rate outcomes didn’t reach significant difference for all 6 studies.
Conclusions
Weekly and triweekly chemoradiation regimens for nasopharyngeal cancer were shown to be similar in terms of overall survival. The choice of weekly or triweekly chemoradiation for nasopharyngeal cancer patient should tailored according to institutional condition and capability.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
195P - HGCSG1601: A retrospective cohort study of the efficacy and safety of nab-paclitaxel plus gemcitabine (nab-P+GEM) for unresectable locally advanced pancreatic cancer (LAPC)
Presenter: Aya Tanimoto
Session: Poster display session
Resources:
Abstract
196P - The tolerability and efficacy of FOLFIRINOX in gastro-oesophageal carcinoma
Presenter: Nicholas Travers
Session: Poster display session
Resources:
Abstract
197TiP - GLOW: Zolbetuximab + CAPOX compared with placebo + CAPOX as first-line treatment for patients with Claudin18.2+/HER2– Locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: A randomized phase III study
Presenter: Rui-Hua Xu
Session: Poster display session
Resources:
Abstract
198TiP - SPOTLIGHT: Comparison of zolbetuximab or placebo + mFOLFOX6 as first-line treatment in patients with claudin18.2+/HER2– locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (GEJ): A randomized phase III study
Presenter: Kensei Yamaguchi
Session: Poster display session
Resources:
Abstract
199TiP - Phase III (COSMIC-312) study of cabozantinib (C) in combination with atezolizumab (A) vs sorafenib (S) in patients (pts) with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy
Presenter: Thomas Yau
Session: Poster display session
Resources:
Abstract
200P - Apalutamide (APA) plus androgen deprivation therapy (ADT) for metastatic castration-sensitive prostate cancer (mCSPC): Analysis of pain and fatigue in the TITAN study
Presenter: Byung Ha Chung
Session: Poster display session
Resources:
Abstract
201P - Efficacy and safety of darolutamide in non-metastatic castration-resistant prostate cancer (nmCRPC) in the ARAMIS trial
Presenter: Jacob See-tong Pang
Session: Poster display session
Resources:
Abstract
202P - What is the best first-line therapy for metastatic castration-sensitive prostate cancer in 2019? A network meta-analysis
Presenter: Tsz Him So
Session: Poster display session
Resources:
Abstract
203P - Long term outcomes of 2-weekly docetaxel in metastatic high-volume hormone sensitive prostate cancer
Presenter: Suhas Singla
Session: Poster display session
Resources:
Abstract
204P - The effect of radium-223 therapy in agent orange related veterans with metastatic castrate resistance prostate carcinoma (CRPC)
Presenter: Andrew Liman
Session: Poster display session
Resources:
Abstract